Richter entered into an asset purchase agreement with Mycenax for the biosimilar tocilizumab
Gedeon Richter Plc. (“Richter”) today announced that it has entered into an asset purchase agreement with Mycenax Biotech Inc. (“Mycenax”) in respect of biosimilar tocilizumab (“Product”) for the treatment of rheumatoid arthritis. According to the agreement Richter receives worldwide rights to develop, manufacture and commercialise the Product. Biosimilar tocilizumab assets comprise the cell lines, intellectual […]